DarioHealth Corp., a leader in the global digital therapeutics (DTx) market, announced today two new employer contracts, including one for the full suite of integrated solutions. The new accounts are scheduled to launch in late 2022 and early 2023.
Insulet can now market Omnipod 5 in Europe for individuals 2 years and older with type 1 diabetes. Acton, Massachusetts–based Insulet said it represents the first CE-marked tubeless hybrid closed loop system
#cgm
The RELIEF study evaluated Abbott’s FreeStyle Libre continuous glucose monitoring (CGM). The findings included the significant reduction of the rate of hospitalizations due to acute diabetes events (ADEs). This study evaluated people living with type 2 diabetes on once-daily (basal) insulin therapy.
#cgm
Medtronic (NYSE:MDT) issued an urgent medical device correction notice to warn of potential issues with some MiniMed automated insulin delivery systems.
#insulin pump
Diabeloop, a leader in therapeutic AI applied to insulin delivery, reports today on 12 months of use of its hybrid closed-loop DBLG1 System on a large, multi-country patient cohort. While Time in Range (70-180 mg/dL) still shows constant improvement, time spent in hypoglycemia stays significantly low. Users share how these clinical results, combined with a growing trust in the algorithm has led to fewer interactions with the device and improved quality of life.
#cgm
#insulin pump
The global digital diabetes management market size is expected to reach USD 21.90 billion by 2030, according to this report. The market is expected to expand at a CAGR of 8.0% from 2022 to 2030. Major factors contributing to the market growth are the growing incidences of diabetes globally, the increasing number of product launches, and innovation in technologies such as predictive analytics and artificial intelligence (AI).
Diabeloop today announced 12-month data supporting its hybrid closed-loop DBLG1 automated insulin delivery system. Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in range and time in hypoglycemia remaining significantly low.
#closed loop
We’re delighted to share the great news from our friends at JDRF as they announce the launch of the Type 1 Diabetes Index (T1D Index). The T1D Index is a first-of-its-kind data simulation tool that measures the human and public health impact of the type 1 diabetes crisis in every country across the globe. Until now, there have been wide gaps in the data about the incidence and impact of type 1 diabetes. Leveraging data and insights from the T1D Index can help change the lives of people living with type 1 diabetes by identifying attainable country-by-country interventions including timely diagnosis, accessible care and funding research that could lead to cures.
Better Therapeutics announced today that it submitted a de novo classification request to the FDA for its BT-001 technology.
#dtx
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2022 on November 3, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).